|
Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup) Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup) conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup) Clinical research trials and Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup) health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup). Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup) Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup) clinical trial. Human subjects frequently get the finest healthcare available for their Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup) condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup)  Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup)
Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup)
For Condition: Chorea,Mental Disorder Diagnosed in Childhood,Obsessive Compulsive Disorder,Streptococcal Infection,Tic Disorder
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: The purpose of this study is to determine whether penicillin prevents the symptoms of Obsessive-compulsive Disorder (OCD) and tic disorders from recurring in children with Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus (PANDAS). A subgroup of children with childhood-onset OCD and/or tic disorders share a common clinical course characterized by dramatic onset and symptom exacerbations following scarlet fever or strep. throat infections. Such infections may be prevented by the prophylactic (preventative dose) administration of antibiotics, such as penicillin. This study will determine the effectiveness of penicillin prophylaxis in preventing relapses of OCD and/or tics in the PANDAS subgroup. Participants receive penicillin for at least one month to ensure that they do not enter the study with a streptococcal infection. Participants are then randomly assigned to receive either penicillin or a placebo for 6 months. Each child has monthly evaluations to monitor levels of antibodies to streptococcus in the blood and to assess the severity of neuropsychiatric symptoms. Any child who has a significant increase in his or her OCD or tics is taken off the randomized medication and put on open-label penicillin for the rest of the study. For more information about this study please visit the Official P.A.N.D.A.S. Web Page at the following web address: http://intramural.nimh.nih.gov/research/pdn/web.htm:
Details: A subgroup of patients with childhood-onset obsessive-compulsive disorder (OCD) and/or tic disorders has been identified who share a common clinical course characterized by dramatic onset and symptoms exacerbations following group A beta-hemolytic streptococcal (GABHS) infections. This subgroup is designated by the acronym PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections). There are five clinical characteristics that define the PANDAS subgroup: presence of OCD and/or tic disorder, prepubertal symptom onset, sudden onset or abrupt exacerbations (relapsing-remitting course), association with neurological abnormalities (presence of adventitious movements or motoric hyperactivity during exacerbations) and temporal association between symptom exacerbations and GABHS infections. In the PANDAS subgroup, periodic exacerbations appear to be triggered by GABHS infections, in a manner similar to that of Sydenham's chorea, the neurological variant of rheumatic fever. Rheumatic fever is a disorder with a presumed post-streptococcal autoimmune etiology. The streptococcal pathogenesis of rheumatic fever is supported by studies that have demonstrated the effectiveness of penicillin prophylaxis in preventing recurrences of this illness. A trial of penicillin prophylaxis in the PANDAS subgroup demonstrated that penicillin was not superior to placebo as prophylaxis against GABHS infections and therefore did not decrease the number of neuropsychiatric symptom exacerbations. The failure to provide prophylaxis against GABHS and neuropsychiatric symptom exacerbations was felt to be secondary to poor compliance. We propose to conduct a parallel study of azithromycin and penicillin prophylaxis to determine if the prevention of GABHS infections in the PANDAS subgroup results in a decrease in neurophychiatric exacerbations. To improve compliance, the medication will be administered from blister packs with the day and time designated for each dose. This will allow us to determine the efficacy of antibiotic prophylaxis against GABHS when the antibiotics are taken as directed. Throat cultures, antibody titers, and symptom ratings will be obtained monthly and used for the determination of a temporal association between the GABHS infections and the neuropsychiatric symptoms. Following a comprehensive baseline evaluation, the participant will be randomly assigned to receive a twelve-month course of either penicillin or azithromycin capsules. We expert that the year long administration of azithromycin or penicillin prophylaxis with adequate compliance will prevent streptococcal infections and result in decreased numbers of neuropsychiatric symptom exacerbations in these children.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Patients must meet criteria for the PANDAS subgroup, including: 1. A tic disorder and/or obsessive compulsive disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders-IV edition. 2. A history of a sudden onset of symptoms or an episodic course with abrupt symptom exacerbations interspersed with periods of partial or complete remission. 3. Onset of neuropsychiatric symptoms prior to puberty. 4. Evidence of an association between streptococcal infections and the onset of exacerbations of symptoms. EXCLUSION CRITERIA: History of rheumatic fever, including rheumatic heart disease and Sydenham's chorea. History of other central nervous system autoimmune disorders such as Lupus (SLE), multiple sclerosis, Devek disease (optic neuritis), and Behcet disease (oculourethral syndrome). History of autism. History of neurologic disorders other than tics and Tourette Syndrome. History of personal or family allergy to penicillin, erythromycin, clarithromycin, or azithromycin; current treatment with pimozide.
Total Enrollment: 200
Location and Contact Information:
National Institute of Mental Health (NIMH) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Lorraine Lougee 3014965323
Additional Information:
Study ID Numbers: 930122; 93-M-0122
Study Start Date: April 13, 1993
Record last reviewed: April 15, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001359
Other Tic Disorder Studies:
1. Botulinum Toxin for the Treatment of Involuntary Movement Disorders
2. Treatment of Huntington's Chorea with Amantadine
3. Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup)
Related Studies:
Other Tic Disorder Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup)
|
|
|
|
|
|
|
|
